DeepMind (Google)

London, UK All United Kingdom companies → — Founded 2010

AI Research Lab Biotech / Drug Discovery General Productivity AI

Endocrinology Infectious Disease Oncology

Clinical Decision Support & Reference Drug Discovery & Research Lab & Diagnostics

Acquired (by Google/Alphabet Inc.) — $1.53B (DeepMind raised over $50 million before acquisition, and Google acquired it for $400-$650 million. Some sources indicate total funding of $1.53 billion or $64.6 million in various rounds.)

Website Claim this company

About DeepMind (Google)

DeepMind, now Google DeepMind, is a leading artificial intelligence (AI) research laboratory focused on developing advanced AI systems to address complex scientific and computational challenges. For physicians and healthcare providers, DeepMind’s work holds significant promise in revolutionizing medical care. Their AI tools are designed to assist in areas such as early disease detection, medical imaging analysis, and clinical decision support. For instance, their AI has demonstrated the ability to outperform trained doctors in early lung cancer detection, predict potential issues days in advance, and reduce false alarms in medical imaging.

One of DeepMind’s most notable breakthroughs, AlphaFold, accurately predicts protein structures, a task that traditionally took scientists years. This capability can significantly expedite drug design and help in understanding disease mechanisms, potentially leading to more accessible and affordable treatments for conditions like cystic fibrosis and Alzheimer’s. DeepMind is also exploring AI co-clinician initiatives to support clinical decision-making and patient care journeys, and developing tools for pandemic preparedness. Their Med-PaLM 2, an AI designed to assist in medical care, has scored highly on medical licensure exams and is being tested in clinics to provide instant, doctor-approved answers and prioritize patient inquiries.

Focus Areas

Artificial General Intelligence (AGI) deep reinforcement learning scientific AI multimodal AI language models protein folding healthcare AI robotics AI safety and ethics coding automation video generation

Business Intelligence

Key Investors	Horizons Ventures, Founders Fund, Elon Musk, Peter Thiel, Jaan Tallinn (prior to acquisition by Google)
Partnerships	NHS hospitals (for lung cancer detection), Beth Israel Deaconess Medical Center (for AMIE clinical research), Included Health (for AI-driven telehealth care), All India Institute of Medical Sciences (for MedGemma applications), Singapore Ministry of Health (for MedGemma fine-tuning), National Research Foundation Singapore (for training local scientists in agentic AI tools), SG Enable (for Gemma-powered running assistant), Infocomm Media Development Authority (IMDA) and MLCommons (for multimodal and multilingual safety benchmarks)
Acquisitions	Dark Blue Labs (acquired by DeepMind in 2014), Common Sense Machines (acquired by Google DeepMind in 2026), Hume AI (licensing deal and talent acquisition in 2026), Contextual AI (licensing deal and talent acquisition in 2026)
Technology	Deep learning, reinforcement learning, neural networks, Transformer architecture, large language models (e.g., Gemini), AlphaFold (for protein structure prediction), Med-PaLM 2 (medical AI assistant), AMIE (multi-agent system for medical reasoning), MedGemma (medical text and image interpretation models)
FDA Clearances	unknown cleared products (estimated)

At a glance

Founded 2010

HQ London, UK · United Kingdom

Team size Approximately 4,000-10,000+ (DeepMind had over 250 employees in 2016, around 700 in 2018, approximately 4,000 in 2026, and 10,288 as of July 2026)

CEO Koray Kavukcuoglu (Senior Vice President, leading day-to-day operations); Demis Hassabis (Chairman and Co-founder)

Funding Acquired (by Google/Alphabet Inc.) — $1.53B (DeepMind raised over $50 million before acquisition, and Google acquired it for $400-$650 million. Some sources indicate total funding of $1.53 billion or $64.6 million in various rounds.)

FDA clearances unknown (estimated)

Visit site